Individualizing therapy using molecular markers in multiple myeloma

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Multiple myeloma is a heterogeneous disease with complex genetics, including a variety of primary and secondary genetic events that contribute to disease pathogenesis. Good risk genetics include hyperdiploidy (approximately 40%) and cyclin D translocations (t[11;14] and t[6;14]; approximately 18%). Poor risk genetics include t(4;14), approximately 15%; MAF translocations (t[14;16]) and t[14;20]; approximately 8%); secondary genetic events such as deletion p53, and abnormal cytogenetics (deletion 13 or hypodiploidy). Proliferation is the other poor risk feature, as measured by either plasma cell labeling index, β2-microglobulin, or gene expression profiling; it is identified in all genetic subtypes and not yet captured by any genetic marker. Altogether, approximately 75% of patients are good risk and if eligible, do well with high-dose melphalan and autologous stem cell transplantation. In contrast, about 25% of the patients have poor risk features and receive only transient benefit from this approach. We propose the Mayo Stratified Myeloma and Risk-Adapted Therapy. Stem cell transplantation is deferred in patients with high-risk molecular markers, and in all patients, response is followed closely and determines the individual timing and sequence of therapeutic regimens.

Original languageEnglish (US)
Pages (from-to)S170-S174
JournalClinical Lymphoma and Myeloma
Issue numberSUPPL. 4
StatePublished - Apr 2007


  • Autologous stem cell transplantation
  • Hyperdiploidy
  • Karyotypic abnormality
  • Melphalan
  • Translocations

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Individualizing therapy using molecular markers in multiple myeloma'. Together they form a unique fingerprint.

Cite this